With public health dominating political and economic discourse amid the Covid-19 pandemic, many investors are looking to broaden their exposure to big pharma. As it turns out, some of the most compelling dividend plays aren’t directly involved in Covid-19 treatment. Case in point is the latest reaffirmation in our Best Healthcare Dividend Stocks List.
Thanks to strong corporate earnings, positive clinical trials for an experimental cardiomyopathy drug and double-digit percentage growth for its blood clot and melanoma treatments, our latest big pharma pick is giving investors many reasons to be optimistic. Our pick yields a respectable 2.8%, which is considerably higher than the healthcare average, and is poised to continue delivering shareholder value after a solid fiscal 2021.
Our pick has a demonstrated history of dividend increases and a global base of customers and patients who depend on its treatments. As such, it’s a compelling option for investors whose portfolio leans toward risk aversion. Watch for the stock when it goes ex-dividend on Tuesday, July 19 (estimated date).
You can check out the Best Healthcare Dividend Stocks List to explore all the stocks.
